-+ 0.00%
-+ 0.00%
-+ 0.00%

Traws Pharma Files Clinical Trial Application With FDA For Tivoxavir Marboxil, a Single Oral Tablet Administered For Influenza, Full Study Enrollment Expected In January 2026

Benzinga·01/13/2026 12:06:27
Listen to the news
  • IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile
  • Updated clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds and faster time to sustained symptom resolution
  • Ratutrelvir's safety and efficacy advantage recapitulated in PAXLOVID®-ineligible patients, representing a significant population with few effective treatment options